Skip to content

Prospective Study Determining the Pain Response, Functional Interference and Quality of Life in Patients Undergoing Radiofrequency Ablation Assisted Vertebroplasty/ Cementoplasty

Prospective Study Determining the Pain Response, Functional Interference and Quality of Life in Patients Undergoing Radiofrequency Ablation Assisted Vertebroplasty/ Cementoplasty

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02082314
Acronym
RFA
Enrollment
10
Registered
2014-03-10
Start date
2014-02-28
Completion date
Unknown
Last updated
2016-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cementoplasty, Neoplasms, Quality of Life

Keywords

radiofrequency ablation, bone metastases

Brief summary

Bone metastases are a cause of significant morbidity in cancer patients. In patients who die from breast, prostate, and lung cancer, autopsy studies have shown that up to 85% have evidence of bone metastases at the time of death (1). These metastases frequently give rise to complications that reduce patients' quality of life. These include: pain, fractures, and decreased mobility, ultimately reducing performance status. Radiofrequency ablation therapy with cementoplasty/vertebroplasty for painful bone metastases has been shown to be feasible, efficacious, and safe. However, patient reported outcomes have yet to be determined.

Interventions

PROCEDURERFA Vertebroplasty

Sponsors

Sunnybrook Health Sciences Centre
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Histologically or cytologically proven malignancy. 2. Patients aged 18 and above. 3. Advanced cancer with bone metastasis(es) to the spine and/or pelvis 4. Symptomatic with axial pain from spinal lesions and at risk for pathological fracture, or, pathological fracture without spinal cord compromise 5. Karnofsky Performance Status (KPS) greater than or equal to 40 at the time of baseline evaluation. 6. Is planned to receive RFA and/or cementoplasty with treatment to all sites being followed for study. 7. Is able to provide worst pain score at bony metastatic site(s). 8. Patient is able and willing to fill out daily diary. 9. Patients must be able to provide informed consent prior to being enrolled to the study.

Exclusion criteria

1. Progressive neurological compromise 2. Pathological fracture of vertebrae with significant cortical involvement or spinal canal compromise 3. Central nervous system metastases 4. Inability to record pain score, complete diary and communicate this to study personnel.

Design outcomes

Primary

MeasureTime frameDescription
Pain responseBaseline to 6 weeks post treatmentTo determine the complete and partial pain response rates in patients who undergo radiofrequency ablation (RFA) and/or cementoplasty/vertebroplasty for spinal/pelvic metastases.

Secondary

MeasureTime frameDescription
Functional InterferenceBaseline - 6 weeks post treatmentTo investigate how functional interference of pain changes
Quality of LifeBaseline - 6 weeks post treatmentTo investigate quality of life changes
Side-effectsBaseline-6 weeks post treatmentTo investigate acute side effects of treatment

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026